Lazarus CDS leverages Artificial Intelligence to improve early cancer detection by turning a primary care doctor into a specialist for 5 minutes. For diseases like cervical cancer, this is as simple as a simple prompt that alerts physicians of high-risk patients, enabling them to make better clinical decisions. In skin cancer, we turn any mobile device into an AI-powered dermascope, automatically classifying risk based on a whole host of factors. Best of all, it's fully explainable. No black boxes, just real results.

Lazarus uses patient health data and AI to detect cancer early. The company has clinical decision support systems for skin and cervical cancer, which help improve the diagnostic accuracy of physicians.

DiagMMR is designed to be a predictive diagnostic tool that enables preventive follow-up and counselling for affected mutation carriers who are at high risk for developing Lynch syndrome related cancers.

While current Lynch syndrome diagnosis relies heavily on tumor studies, the quantitative DiagMMR method allows carrier diagnosis based on a minimally invasive tissue sample before the person has developed any cancer, without the knowledge and details of an inherited mutation.

The inherent challenges to variant interpretation in genetic testing can be avoided and the conclusive and actionable results removes the burden of uncertainty from both the patients and the treating medical professionals.

LS CancerDiag Ltd is committed to reducing cancer mortality rates with a low-cost, simple diagnostic method that detects an inherited cancer-causing condition prior to cancer. Their vision is to see DiagMMR™ as a new global testing standard in LS diagnostics. Lynch syndrome is the main cause of hereditary colorectal cancers and it also causes a broad spectrum of other tumors. With a significant proportion of the world’s population carrying the Lynch syndrome mutation, there are potentially tens of millions under a severe risk for being affected by LS. Their groundbreaking DiagMMR™ assay is an easy functional test that can be used for diagnosis of MMR deficiency i.e. Lynch syndrome (previously known as Hereditary Non­Polyposis Colorectal Cancer; HNPCC). Their mission is to save lives through an innovation that dramatically simplifies diagnostics of Lynch syndrome by delivering predictive and accurate results with a fast, unique and cost-efficient method globally.